Jennifer L. Caswell Jin

Jennifer L. Caswell Jin

Auto-generated profile, based on publicly available information

Jennifer L. Caswell Jin

Stanford University School of Medicine, Stanford, CA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
OROscar M. Rueda
Oscar M. Rueda
SSStephen-John Sammut
Stephen-John Sammut
JSJose A. Seoane
Jose A. Seoane
SCSuet-Feung Chin
Suet-Feung Chin
JCJennifer L. Caswell-Jin
Jennifer L. Caswell-Jin
CCChristina Curtis
Christina Curtis

7 May 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
NANasim Ahmadiyeh
Nasim Ahmadiyeh
MPMark M. Pomerantz
Mark M. Pomerantz
CGChiara Grisanzio
Chiara Grisanzio
PHPaula Herman
Paula Herman
LJLi Jia
Li Jia
MFMatthew Freedman
Matthew Freedman
The 8q24 gene desert contains risk loci for multiple epithelial cancers, including colon, breast, and prostate. Recent evidence suggests these risk loci contain enhancers. In this study, data are presented showing that each risk locus bears epigenetic marks consistent with enhancer elements and forms a long-range chromatin loop with the MYC proto-oncogene located several hundred kilobases telomeric and that these interactions are tissue-specific. We therefore propose that the 8q24 risk loci operate through a common mechanism—as tissue-specific enhancers of MYC .

1 October 2018 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
JCJennifer L Caswell-Jin
Jennifer L Caswell-Jin
SPSylvia K Plevritis
Sylvia K Plevritis
LTLu Tian
Lu Tian
CCChristopher Cadham
Christopher Cadham
CXCong Xu
Cong Xu
AKAllison W Kurian
Allison W Kurian
Background: Metastatic breast cancer (MBC) treatment has changed substantially over time, but we do not know whether survival post-metastasis has improved at the population level. Methods: We searched for studies of MBC patients that reported survival after metastasis in at least two time periods between 1970 and the present. We used meta-regression models to test for survival improvement over time in four disease groups: recurrent, recurrent estrogen (ER)-positive, recurrent ER-negative, and de novo stage IV. We performed sensitivity analyses based on bias in some studies that could lead earlier cohorts to include more aggressive cancers. Results: There were 15 studies of recurrent MBC (N = 18 678 patients; 3073 ER-positive and 1239 ER-negative); meta-regression showed no survival improvement among patients recurring between 1980 and 1990, but median survival increased from 21 (95% confidence interval [CI] = 18 to 25) months to 38 (95% CI = 31 to 47) months from 1990 to 2010. For ER-positive MBC patients, median survival increased during 1990–2010 from 32 (95% CI = 23 to 43) to 57 (95% CI = 37 to 87) months, and for ER-negative MBC patients from 14 (95% CI = 11 to 19) to 33 (95% CI = 21 to 51) months. Among eight studies (N = 35 831) of de novo stage IV MBC, median survival increased during 1990–2010 from 20 (95% CI = 16 to 24) to 31 (95% CI = 24 to 39) months. Results did not change in sensitivity analyses. Conclusion: By bridging studies over time, we demonstrated improvements in survival for recurrent and de novo stage IV MBC overall and across ER-defined subtypes since 1990. These results can inform patient-doctor discussions about MBC prognosis and therapy.

1 February 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
JCJennifer L. Caswell-Jin
Jennifer L. Caswell-Jin
TGTanya Gupta
Tanya Gupta
EHEvan T. Hall
Evan T. Hall
IPIva M. Petrovchich
Iva M. Petrovchich
MMMeredith A. Mills
Meredith A. Mills
AKAllison W. Kurian
Allison W. Kurian

20 October 2014 in Nature Communications
Verified
Journal Article
Open access
LFLaura Fejerman
Laura Fejerman
NANasim Ahmadiyeh
Nasim Ahmadiyeh
DHDonglei Hu
Donglei Hu
SHScott Huntsman
Scott Huntsman
KBKenneth B. Beckman
Kenneth B. Beckman
EZElad Ziv
Elad Ziv
The genetic contributions to breast cancer development among Latinas are not well understood. Here we carry out a genome-wide association study of breast cancer in Latinas and identify a genome-wide significant risk variant, located 5′ of the Estrogen Receptor 1 gene (ESR1; 6q25 region). The minor allele for this variant is strongly protective (rs140068132: odds ratio (OR) 0.60, 95% confidence interval (CI) 0.53–0.67, P=9 × 10−18), originates from Indigenous Americans and is uncorrelated with previously reported risk variants at 6q25. The association is stronger for oestrogen receptor-negative disease (OR 0.34, 95% CI 0.21–0.54) than oestrogen receptor-positive disease (OR 0.63, 95% CI 0.49–0.80; P heterogeneity=0.01) and is also associated with mammographic breast density, a strong risk factor for breast cancer (P=0.001). rs140068132 is located within several transcription factor-binding sites and electrophoretic mobility shift assays with MCF-7 nuclear protein demonstrate differential binding of the G/A alleles at this locus. These results highlight the importance of conducting research in diverse populations.

18 September 2018 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JCJennifer L Caswell-Jin
Jennifer L Caswell-Jin
AZAnjali D Zimmer
Anjali D Zimmer
WSWill Stedden
Will Stedden
KKKerry E Kingham
Kerry E Kingham
AZAlicia Y Zhou
Alicia Y Zhou
AKAllison W Kurian
Allison W Kurian
In cascade testing, genetic testing for an identified familial pathogenic variant extends to disease-free relatives to allow genetically targeted disease prevention. We evaluated the results of an online initiative in which carriers of 1 of 30 cancer-associated genes, or their first-degree relatives, could offer low-cost testing to at-risk first-degree relatives. In the first year, 1101 applicants invited 2280 first-degree relatives to undergo genetic testing. Of invited relatives, 47.5% (95% confidence interval [CI] = 45.5 to 49.6%) underwent genetic testing, and 12.0% (95% CI = 9.2 to 14.8%) who tested positive continued the cascade by inviting additional relatives to test. Of tested relatives, 4.9% (95% CI = 3.8 to 6.1%) had a pathogenic variant in a different gene from the known familial one, and 16.8% (95% CI = 14.7 to 18.8%) had a variant of uncertain significance. These results suggest that an online, low-cost program is an effective approach to implementing cascade testing, and that up to 5% of the general population may carry a pathogenic variant in 1 of 30 cancer-associated genes.